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The dopamine transporter (SLC6A3, DAT) sequesters synaptic dopamine (DA) into 
presynaptic nerve terminals (Amara and Kuhar 1993; Cragg and Rice 2004; Gainetdinov 
and others 2002; Giros and Caron 1993; Torres and others 2003). SLC6A3 may contribute 
to voluntary movement, reward and cognitive function (Mozley and others 2001; Sotnikova 
and others 2006). As expression of the transporter varies across brain regions, it is 
considered a critical spatio-temporal regulator of synaptic DA activity (Amara and Kuhar 
1993; Cragg and Rice 2004; Giros and Caron 1993). In humans, the highest levels of 
SLC6A3 are present in the striatum, with much lower levels in the neocortex (Hall and 
Strange 1999) (Farde and others 1994). SLC6A3 is localized to chromosome 5p15.3 and 
spans approximately 60 kb (Giros and others 1992) (Vandenbergh and others 1992a). It 
incorporates 15 exons, with the protein-coding portion spanning exons 2–15 (Bannon and 
others 2001). To date only the full length transcript has been described; alternative splicing 
has not been demonstrated at this locus.
The core promoter sequences for SLC6A3 have been identified (Kelada and others 2005) 
(Bannon and others 2001). Promoter sequence analysis of human SLC6A3 did not reveal 
conventional ‘TATA’ or ‘CAT’ boxes upstream of the transcription initiation site (Kawarai 
and others 1997). A 180 bp GC rich sequence incorporating multiple Sp1 sites may direct 
transcription (Bannon and others 2001). Several other transcription-regulating factors have 
been identified, including NURR1, HEY1/HESR and Sp1/Sp3 (Fuke and others 2005) 
(Michelhaugh and others 2005) (Wang and Bannon 2005) (Bannon and others 2002). We 
have recently identified a novel promoter regulatory domain flanking rs3756450 (Bamne 
and others 2009). It has been relatively difficult to understand the control of SLC6A3 
expression because of the unavailability of neuronal cell lines stably expressing SLC6A3 
(Bannon and others 2001).
SLC6A3 polymorphisms have been frequent targets for conventional candidate gene 
association studies of various psychiatric disorders, including schizophrenia (SZ) and 
schizoaffective disorder (SZA). Most studies considered only one variant, a functional 
variable number tandem repeat polymorphism (VNTR) in the 3′-UTR with inconsistent 
results (reviewed by (Talkowski and others 2007). Following systematic analysis of DA 
gene variations, we found replicated SNP-based associations and epistatic interactions 
between pairs of SNPs localized to four genes, including SLC6A3 (Talkowski and others 
2008). The majority of the associations and interactions involved SNPs localized to introns 3 
and 4 of SLC6A3. We also observed possible functional allelic effects with two of the SNPs 
in vitro (rs3756450 in the 5′ untranslated region and rs464049 within intron 4) (Talkowski 
and others 2008). In the present study, we attempted to understand the complete pattern of 
linkage disequilibrium across SLC6A3, refine the statistical associations to a finite genomic 
region, and investigate plausible biological mechanisms underlying these observed 
associations. We report the discovery of novel alternative splicing of SLC6A3 within intron 
3 that is influenced by intronic sequence variants.
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We sequenced coding and non-coding regions spanning SLC6A3 and identified a 
comprehensive set of tag SNPs to test for statistical associations to schizophrenia in two 
independent samples. Further replication was sought in published genome-wide association 
studies (GWAS). We then conducted computational analysis to identify plausible alternative 
splice sites spanning the putatively associated region, followed by in vitro and in vivo 
studies to confirm the predicted transcript. Finally, we investigated factors affecting the 
alternative splicing in cell transfection assays and human post-mortem brain tissue.
Sequencing and Genetic association studies
Approximately 24,778 bp of SLC6A3 were sequenced to supplement the Seattle SNPs 
Polymorphism Discovery Resource (PDR90) (Rieder and others 2008) (see Supplementary 
methods section). All novel variants detected were sequenced in 32 unrelated CEPH 
individuals and merged with HapMap (www.HapMap.org) (Supplementary Figure SF1d and 
SF1e). Since CEPH samples are not included in PDR90, the Hapmap and PDR90 datasets 
could not be merged. We chose SNPs with high redundancy (r2 < 0.95) from both datasets. 
Genotype assays for 88 SNPs were initially designed using the ABI SNPlex assay. Two 
VNTRs were also evaluated, the frequently studied 3′ UTR variant (Vandenbergh and others 
1992a) and a novel VNTR in intron 3 (Miyajima and others 2006).
We initially evaluated two Caucasian ancestry samples: 1) a discovery sample of SZ/SZA 
case-parent families from Bulgaria, recruited through Cardiff University; 2) a replicate 
sample of SZ/SZA cases and unscreened controls from Pittsburgh (PITT) (Kirov and others 
2004; Talkowski and others 2008). The cases in these samples differed by gender (males: 
50% Bulgaria, 64% PITT samples), and frequency of SZA (12.6% Bulgaria, 41.7% US). 
Recruitment was approved by the University of Pittsburgh IRB for PITT samples. For UK 
and Bulgarian samples, Ethics committee approval was obtained from all regions where 
patients were recruited.
After initial replication in two samples we investigated consistency with available GWAS 
samples. For these analyses, Caucasian ancestry individuals were abstracted from three 
published datasets. The Molecular Genetics of Schizophrenia (MGS) sample included 
individuals with SZ or SZA and screened adult controls (Shi and others 2009). The Clinical 
Antipsychotic Trials of Intervention Effectiveness (CATIE) included SZ/SZA cases (Stroup 
and others 2006) and MGS controls (Sullivan and others 2008). To avoid overlap between 
CATIE and MGS samples, 1000 independent SNPs with MAF > 0.4 were used to estimate 
identity by state (IBS) using PLINK software v1.06 (Purcell and others 2007). Samples with 
identical IBS estimates were excluded from MGS (n = 199). We also surveyed the 
International Schizophrenia Consortium (ISC) sample that included cases from seven sites 
diagnosed using DSM-IV, International Classification of Diseases (ICD-10) criteria, or 
clinical diagnoses. Controls were selected from each site (Purcell and others 2009).
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Bulgarian and PITT samples—The SNPlex assay was used for initial analyses in the 
Bulgarian families (n = 88 SNPs) (Tobler and others 2005) (Talkowski and others 2008). 
SNaPshot assays (Applied Biosystems) (Mansour and others 2005) were used for the PITT 
samples and for follow up. The VNTRs were PCR amplified and resolved using agarose gel 
electrophoresis (Vandenbergh and others 1992b) (Miyajima and others 2006)
Quality control for PITT and Bulgarian samples—Duplicate samples were included 
in each genotype assay, along with negative controls and CEPH individuals. Among the 88 
selected SNPs, 8 SNPs failed quality control filters (95% genotype success rate; Hardy-
Weinberg Equilibrium p > 0.01; < 1% Mendelian errors; duplicate control concordance > 
99.5%). Nine other SNPs were not sufficiently polymorphic (minor allele ≤ 2%), leaving 71 
SNPs. Of these, 27 SNPs were independently genotyped by Illumina (Illumina Inc) for 
another project (10819 duplicate genotypes, 99.78% concordance rate).
The MGS and ISC cohorts were genotyped using various Affymetrix arrays (Purcell and 
others 2009). CATIE samples were analyzed with a Perlegen31 array (Sullivan and others 
2008).
Alternative splicing analysis
Analyses in human post mortem brain—Because of the low abundance of E3b(+) 
relative to E3b(−) mRNAs in brain, a nested RT-PCR strategy was used to confirm the 
presence of E3b in a subset of the SLC6A3 mRNAs from human post-mortem substantia 
nigra (see Supplemental Methods for full details and primer sequences).
Statistical Analysis
Mendelian inconsistencies and Hardy Weinberg equilibrium (HWE) were evaluated using 
PEDCHECK (O’Connell and Weeks 1998) and GENEPOP (version 1.31) software, 
respectively. Transmission distortion was assessed using FBAT (Laird and others 2000). 
Case-control genotype distributions were compared with the Armitage Trends test (SAS 
software) (Armitage 1955) or CLUMP software for VNTRs (Sham and Curtis 1995). 
Imputation was performed using MACH 1.0.16 (http://www.sph.umich.edu/csg/abecasis/
MaCH). Analysis of imputed SNP dosage values was conducted using proc logistic in SAS. 
Comparisons of demographic and clinical variables utilized SPSS 16.0 software package. 
Power was computed using Quanto v1.2.4 (Gauderman 2002). Meta analysis utilized a 
weighted z score method (de Bakker and others 2005).
RESULTS
I. Genetic Association Studies
Polymorphism detection and selection—After searching a publicly available 
sequence database (Seattle SNPs) (Rieder and others 2008), we performed complementary 
in-house sequencing in an effort to identify a set of tag SNPs representing a comprehensive 
catalog of common SLC6A3 polymorphisms (minor allele frequency, MAF > 5%). We 
estimate that this combined effort successfully surveyed 80.9% of the SLC6A3 genomic 
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sequence for common variation (62,419 bp; gene and selected flanking sequence). 
Following QC and allele frequency filters described above, we ultimately tested 71 SNPs 
and two VNTRs, resulting in an average coverage of 1 SNP/879 bp across the genomic 
region surveyed. Five additional SNPs were genotyped during fine-grained regional analysis 
in the replication sample (76 total SNPs and 2 VNTRs genotyped overall). We estimate our 
SNP genotyping concordance rate to be 99.78% (see Methods).
Family based association tests—All 71 SNPs were analyzed for transmission 
distortion among 644 families from Bulgaria. Nominally significant associations were 
detected with five SNPs listed in Table 1 and rs3756450, a SNP in the 5′-utranslated region 
(p ≤ 0.05, see supplementary table ST2). Transmission distortion was noted for nine 
additional SNPs that did not reach nominal statistical significance (0.1 > p > 0.05) 
(supplementary table ST2; see Figure 1). Of these 15 SNPs, 8 were localized to introns 3 
and 4; two others were intron 6 SNPs in high LD with intron 3/4 SNPs (rs37020 & rs37021; 
r2 > 0.8).
Replication analyses—A US case-control cohort from Pittsburgh (PITT) was analyzed 
for replication (491 cases/540 controls). Of the six nominally associated SNPs from the 
Bulgarian sample, replication of rs464049 and rs3756450 have already been published 
(Talkowski and others 2008). The remaining 4 SNPs, and all other intron 3/4 SNPs with 
trends for association, could be represented at r2 > 0.95 using 3 SNPs (rs420422, rs37020, 
rs465130). All three of these tag SNPs replicated in the US sample (rs420422, p = 0.014; 
rs37020, p = 0.006; rs465130, p = 0.002). Risk alleles were identical between samples, and 
the largest effect size was observed with rs465130 (odds ratio for risk allele = 1.40, 95% 
confidence interval: 1.13 – 1.73) (Table 1). The pattern of test statistics and LD analyses 
identified two distinct clusters associated with SZ (see Supplementary Figure SF1a), 
denoted clusters 1 and 2 herein. These fine-mapping analyses thus indicated the possible 
presence of risk allele/s within a 12.5 kb region spanning introns 3 and 4 of SLC6A3. In an 
effort to further refine the associations, we conducted additional sequencing and LD 
analyses using CEPH samples. We genotyped 5 additional common SNPs across intron 3 in 
the PITT case-control sample (Table 1). Four of the five SNPs were associated with SZ. 
Notably, the associated probabilities and confidence intervals were of equal or greater 
significance than any of the SNPs already tested (Table 1).
Two VNTRs were also evaluated in the PITT samples, the frequently studied variant in the 
3′ UTR (Vandenbergh and others 1992a) and a recently identified VNTR in the third intron 
(Prof J Quinn, personal communication) (see Supplementary Table ST1). Significant LD 
was not present between the 3′ VNTR and any of the tag SNPs in introns 3 or 4 (r2 < 0.1; 
data not shown), while the intron 3 VNTR is in significant LD with cluster 1 SNPs (r2 = 
0.83 with rs460000 among cases). Nominally significant associations were detected at both 
VNTRs (p ≤ 0.05; Supplementary Table ST2).
Haplotype-based analyses—To extract additional information and to gain insight into 
the possible impact of unknown rare variation, we used our sequencing data and HapMap to 
evaluate haplotype frequencies across this genomic region (intron 3 to the start of exon 4, 
i.e. rs462523 to rs460000). We found that haplotypes incorporating three htSNPs 
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represented the majority of predicted haplotypes. Association tests of these haplotypes were 
highly significant, with an over-representation of the most common haplotype in case 
samples and greater diversity of less common haplotypes among controls (rs420422-
rs458609, χ2=40.5, df = 3, p = 8.36 × 10−9; rs460000-rs420422, χ2 = 8.096, df = 3, p = 
0.017; Supplementary Table ST3). Similar associations were also detected in the Bulgarian 
dataset (rs420422-rs456082, χ2=9.596, df = 2, p = 0.008). Adding information from the 3′-
VNTR did not substantially increase the associations (details in supplementary table ST3).
Genome-wide association studies—Following the replication, we tested the 
generalizability of our observed results in available GWAS (see Methods). In sum, we 
analyzed 9,119 independent Caucasian case-control samples after filtering for duplicate 
samples between studies and overlap with cases from our initial discovery sample. These 
samples had over 90% power to detect the initial associations. Nominally significant 
associations were noted with three SNPs (rs11564772, p = 0.001; rs6869645, p = 0.0008, 
and rs40358, p = 0.049, (Supplementary Table 5)). Statistically significant replication was 
not observed with any SNPs from our discovery sample nor was meta-analysis significant 
across all samples.
Meta analysis—We combined p-values by a weighted Z method using a tag SNP from 
each of the significant clusters, preferentially choosing a SNP directly measured in the 
discovery sample (cluster 1: rs464061, cluster 2: rs420422). Combined results were 
significant for cluster 1 when p-values were weighted by sample size (p = 0.005), but neither 
cluster was significant when we accounted for contrasting risk alleles between the initial 
samples and GWAS samples (cluster 1 rs464061, p = 0.133; cluster 2 rs420422, p = 0.563).
II. Prediction of alternative splicing
The fine-mapping analyses indicated possible risk allele/s within approximately 12.5 kb 
spanning introns 3 and 4 of SLC6A3. Given the intronic location of most of the associated 
SNPs and the intron 3 VNTR, it appeared plausible that they could alter SLC6A3 function 
or expression by effects on alternative splicing. Examination of the 9 kb intron 3 sequence 
revealed a candidate cassette exon (named E3b herein) ~6kb downstream of exon 3 (Figure 
1; see Supplementary Methods for details of analysis). E3b is defined by tandem 3′ splice 
site motifs (reviewed in (Hiller and Platzer 2008) that are separated by 4 nucleotides (nt) 
followed by multiple 5′ splice site motifs spanning a region of 363 bp. In the human 
sequence, the closest of these 5′ splice sites is located 108 bp downstream of the intron-
proximal 3′ splice site (Figure 1). Notably, four SNPs associated with SZ either by direct 
measurement or via LD are located within 600 bp of E3b (Figure 1, Figure SF1a).
Phylogenetic analysis of intron 3 (8.2 kb) revealed strong conservation of a 1-kb segment 
containing the predicted exon E3b among the seven simian primates for which SLC6A3 
sequence was available (Figure 2). Tandem 3′ splice site motifs are present in all seven 
species, although the intron-proximal site is more optimal in Gibbon, Macaque and 
Marmoset, where the spacing is also greater by 1 nt. In all species, use of either 3′ splice site 
to include exon E3b would bring an early stop codon into frame, suggesting that alternative 
splicing of this exon could serve a negative regulatory role by truncating the open reading 
Talkowski et al. Page 6













frame (ORF). Genotypic variation for E3b splicing or its regulation could thus be 
functionally relevant, because increased inclusion of E3b should result in decreased 
expression of full-length SLC6A3 protein. Exon E3b sequences were found in most other 
mammals but were not noted in rodents or lagomorphs, precluding meaningful studies using 
rodent animal models (Supplementary Methods and Figures SF2–SF4).
III. Functional analyses
III A. Analysis of E3b splicing in post-mortem brain samples—Inclusion of E3b is 
not documented in current mRNA or EST databases. However, inclusion of E3b would 
truncate the ORF early and more than 55 nt upstream of the E3b/E4 exon junction. This is 
expected to trigger degradation of E3b(+) mRNAs by the nonsense-mediated decay pathway 
(NMD) (Stalder and Muhlemann 2008). Thus, it could be difficult to detect E3b inclusion in 
standard cDNA or EST screens even if this splicing event were relatively frequent. To 
evaluate whether alternative splicing of E3b occurs in vivo, RT-PCR assays were conducted 
using mRNA extracted from post-mortem brain regions of unaffected individuals. These 
analyses focused on the substantia nigra, where SLC6A3 mRNA is known to be expressed at 
relatively high levels. Preliminary RT-PCR analyses spanning exons E3-E4 indicated that 
E3b-containing mRNAs [designated E3b(+)] accumulate only to very low levels compared 
to E3b(−) mRNAs, as anticipated. Therefore, we used a nested RT-PCR strategy to confirm 
that E3b is included in a subset of otherwise canonical SLC6A3 mRNAs (Figure 3, left 
panel). First, oligo-dT-primed SLC6A3 cDNAs spanning from exon 2 (beginning of the 
ORF) through exon E15 (end of the ORF) were amplified by low-cycle PCR (20 cycles). 
These reactions were diluted 4000-fold and re-amplified with up to 27 cycles using different 
combinations of nested primers to detect inclusion of E3b (Figure 3, right panel). E3b(−) 
amplimers, but not E3b(+), could be detected with 22 or fewer nesting cycles using primers 
in the exons that flank E3b. Higher cycling with these primers resulted in overwhelming 
E3b(−) signals before E3b(+) isoforms could be detected (not shown). However, the E3b(+) 
isoforms could be detected consistently with 27 nesting cycles using forward or reverse 
primers in E3b, which avoided the overwhelming signal from E3b(−) amplimers (Figure 3, 
right panel). These experiments confirmed splicing of E3b to E2/E3 on its 5′ side and to 
E4/E5 on its 3′ side in the context of mRNAs that span E2 through E15. The identity of 
E3b(+) amplimers was verified by sequencing, which also confirmed the splice junctions, 
including use of the two predicted tandem 3′ splice sites (Figure 3, bottom panel) that can 
not be distinguished on gels. Use of two alternative 5′ splice sites for Exon E3b was 
observed (Figure 3); these 5′ splice sites correspond to the two sites noted in Figures 1 and 2 
and are also the most proximal and most distal 5′ splice sites observed in cell transfections 
(Figure 4). Additional large amplimers were observed with the E2->E3b and E3->E3b 
reactions (Figure 3 lanes 3 and 4); these amplimers may represent additional alternative 
splicing events within the E3-proximal region of intron 3, but their identity has not been 
investigated. Alternative splicing of E3b was also observed in substantia nigra from 18 
additional individuals using quantitative RT-PCR (see IIIC below). Although the 
experiments of Figure 3 were not designed to be quantitative, we estimate from the data an 
E3b−/E3b+ ratio of 100–150. This is within the ranges observed in the quantitative RT-PCR 
experiments of section IIIC with substantia nigra samples from non-affected individuals 
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(E3/E3b range=64–1024, mean=367, SD=237) and affected individuals (E3/E3b range=10–
549, mean=259, SD=167).
III B. Cell transfection assays—To test functional correlates of allelic variation, the 
impact of two common intron 3 haplotypes on E3b splicing was investigated. A set of cell 
transfection constructs was generated that placed the native genomic region of SLC6A3 
extending from within exon 3 through all of intron 3 and into exon 4 under the control of the 
CMV promoter and the SV40 early cleavage/polyadenylation site (Figure 4). The constructs 
were designed to eliminate potential translation initiation sites upstream of E3b; this was 
intended to minimize degradation of E3b+ mRNA by nonsense-mediated decay. The 
SLC6A3 fragment in each construct of this series was derived from a different CEPH or 
PITT genomic DNA sample so that each construct contained only the risk alleles at all the 
known risk-associated SNPs within intron 3 (the “PITT risk haplotype”: 5 constructs) or 
only the non-risk-associated alleles (the “PITT non-risk haplotype”: 5 constructs). The 
constructs also differed in sequence at other SNP positions not known to be associated with 
differential SZ risk and at the VNTR located within intron 3. After transfection into the 
human neuroblastoma cell line SHSY-5Y or into HeLa cells, RNA transcribed from the 
constructs was analyzed by RT-PCR using a forward primer targeting vector sequences 
between the transcription start site and SLC6A3 exon E3 together with a reverse primer 
targeting SLC6A3 exon E4. These primers did not detect expression of endogenous SLC6A3, 
as shown by untransfected controls (Figure 4). As anticipated, the most abundant construct-
derived RNA observed had the E3b(−) splicing pattern. A set of alternatively spliced RNAs 
was also observed that correspond to inclusion of E3b using four alternative 5′ splice sites 
(Figure 4 and data not shown). Quantification of the amplimer signals revealed that 
inclusion of exon E3b was elevated in RNA derived from the PITT risk-associated 
haplotype constructs compared with RNA derived from the PITT non-risk haplotype 
constructs (Figure 4). The same was observed after transfection into both SH-SY5Y and 
HeLa cells. These results were confirmed with multiple replicates and the difference in E3b 
inclusion between risk and non-risk constructs was found to be highly significant (Figure 4). 
The Wilcoxon’s rank sum test indicated that the differences in average values for percent 
E3b inclusion between PITT risk and non-risk constructs was significant at P<0.005 
(wnonrisk = 15, wrisk = 40). Analysis of variance showed that the differences in average E3b 
inclusion across the entire set of constructs were significant (F=4.25, P<0.01), whereas 
those among PITT risk or non-risk constructs were not (Frisk=0.938; Fnonrisk = 0.39; 
P≫0.05 in both cases). Application of Student’s t-test to the pooled PITT risk versus pooled 
non-risk data confirmed that inclusion of E3b was significantly higher for risk than for non-
risk constructs (t=5.85, P<0.001).
We mapped the approximate location of sequence variations responsible for increased 
inclusion of E3b by swapping the region extending from genomic coordinates 1487252 to 
1488492 (−519 to +721 relative to the first 3’ss of E3b) between a risk and a non-risk 
construct (derived from CEPH samples 12155 and 12249, respectively). The results showed 
that exchanging this region was sufficient to confer elevated E3b inclusion on the otherwise 
unaltered 12155 non-risk construct (Figure 5). The swapped region contains the four 
previously identified PITT SZ-associated SNPs that immediately flank E3b (rs462523 
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through rs458609) plus two additional single-nucleotide differences that were identified 
between risk and non-risk haplotypes during sequencing of the CEPH panel samples. The 
new polymorphisms were at nt 1487928 (45 nt downstream of the first 3’ss for E3b; G in 
CEPH 12249, T in 12155) and at nt 1487382 (591 nt downstream of the first 3’ss for E3b; C 
in CEPH 12249, T in 12155).
III C. Quantification of alternative transcripts in post-mortem tissue—Samples 
of post-mortem substantia nigra RNA from SZ cases (n = 9) and controls (n = 9) (CCNMD) 
were assayed using qPCR with probes specific for E3b(+) or E3b(−) SLC6A3 mRNA 
(details of clinical samples in (Hashimoto and others 2005). The qPCR reactions using the 
E3b− and the E3b+ probes were performed separately in triplicate for each sample. All 
assays included a probe for GAPDH as a reference. We used the comparative Ct method to 
estimate E3b+ and E3b− levels in tissue samples from cases and controls. To standardize for 
the input amount of RNA, a ΔCt value for each target was determined by subtracting the 
GAPDH Ct value from the respective E3b+ or E3b− Ct values. As the total amount of DAT 
transcript may vary across samples, we examined the proportion of E3b+ transcripts relative 
to total DAT transcripts. Given the relatively low levels of E3b+, this is approximately the 
same as the ratio of E3b+ to E3b− RNA, which is estimated by ΔΔCt (ΔCt for E3b+ minus 
ΔCt for E3b−). The means of triplicate values are displayed in Figure 6. Note that lower ΔCt 
or ΔΔCt values indicate higher quantities or proportions of the transcript. As comparisons 
were made within each sample, corrections for standard variables such as post-mortem 
variables and age were not applied. The case and control samples did not differ significantly 
with regard to these variables (Hashimoto and others 2005). There was significant inverse 
correlation between the E3b− ΔCt values and the (E3b+/E3b−) ΔΔCt proportions (r = 
−0.796 for the entire sample, p = 7.64×10−5, n = 18, total). The correlation remained 
significant even if one outlier value was discarded (see Figure 6, r = −0.565, p = 0018). No 
significant case-control differences were noted with regard to (E3b+/E3b−) ΔΔCt 
proportions.
DISCUSSION
During the course of comprehensive fine-mapping studies of SLC6A3, we identified a novel 
cassette exon, designated E3b. To our knowledge, this is the first report of alternative 
splicing (AS) at SLC6A3. Following in silico analyses, alternative splicing of E3b was 
observed in human substantia nigra, where the majority of DA neurons in the brain 
originate. Although the E3b+ amplimers generated during the RT-PCR assays with brain 
RNA were much less abundant than the E3b− products, our experiments suggest they are 
unlikely to be artifacts originating from genomic DNA or from partially spliced nascent 
RNA species. Amplimers representative of E3b splicing to both the upstream exon (E3) and 
the downstream exon (E4) were obtained by nested PCR of primary low-cycle amplimers 
spanning E2-E15 that could not span the unprocessed introns. Furthermore, performing the 
same number of cycles with E3b primers without the primary amplification from E2 to E15 
did not yield any products (not shown). In addition, the amplimers were observed only after 
reverse transcription, and their identity was verified by sequencing to confirm that they 
represent the spliced RNAs. Finally, similar splicing of E3b from SLC6A3 minigenes was 
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also observed in cell transfection assays where inclusion of E3b between E3 and E4 could be 
assayed directly.
Steady-state levels of E3b+ RNA in the brain appear to be very low. This may be a 
consequence of nonsense-mediated decay triggered by the premature termination codons 
within E3b, but E3b could also be a rarely spliced non-functional exon that becomes 
deleterious when its inclusion is stimulated in certain genetic backgrounds. A selectively 
advantageous function for E3b is suggested by the observation that an ORF-truncating exon 
is predicted at the same position as E3b not only in simians but also in the SLC6A3 genes of 
representatives from seven of the nine Eutherian orders for which sequence is available 
(Supplementary Figures SF2, SF3 and SF4). The boundary positions and exact sequence of 
this exon are not strictly conserved, but this may be expected if its function is solely to 
truncate the ORF.
E3b incorporates multiple stop codons that cause early truncation of the SLC6A3 ORF and 
are expected to trigger nonsense-mediated decay of the mRNA. Thus, protein products 
incorporating E3b would not be predicted, and an increase in E3b splicing should lead to a 
decrease in total SLC6A3 mRNA and DAT protein. We have tested this hypothesis using 
available post-mortem human substantia nigra (SN) tissue. Variations in the levels of E3b 
inclusion and total SLC6A3 mRNA were noted in the predicted directions (Figure 6). To 
evaluate whether this mechanism could also be the basis for increased SZ risk associated 
with the observed haplotypes in the PITT/Bulgarian samples that increase E3b splicing, we 
tested a relatively small post-mortem sample (n = 18, total, cases + controls). No significant 
differences were observed, though a larger sample may provide a more convincing test of 
the hypothesis.
Prior post-mortem studies of SLC6A3 mRNA or protein levels using similarly sized samples 
have not consistently detected reduction among cases (Akil and others 1999; Dean and 
Hussain 2001; Hirai and others 1988; Hitri and others 1995; Seeman and Niznik 1990). 
Brain imaging studies have also yielded mixed results (Laakso and Hietala 2000; Laruelle 
and others 2000; Prata and others 2009; Schmitt and others 2006; Sjoholm and others 2004; 
Yang and others 2004; Yoder and others 2004), though some investigators have replicated 
reduced SLC6A3 binding in the striatum among drug naïve, first episode patients (Mateos 
and others 2005) (Mateos and others 2007). The variable results suggest that case-control 
differences in SLC6A3 transcription or translation, if present are modest. These processes 
are also likely to be impacted by additional trans-acting factors and genomic variation, as 
demonstrated in the present study.
The proposed role of E3b alternative splicing in regulating SLC6A3 functional protein 
expression is similar to the classic examples of Sxl and tra regulation during sex 
determination in Drosophila (reviewed in (Black 2003). Expression of the SXL and TRA 
proteins is controlled by alternative splicing events that introduce early stop codons. 
Approximately 45% of alternative splicing events in humans introduce early stop codons, 
suggesting that ORF truncation and NMD may play a widespread role in quantitative 
regulation of mRNA and protein expression by alternative splicing (Lejeune and Maquat 
2005) (Stalder and Muhlemann 2008).
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Alternative splicing is particularly common among brain-expressed genes (Black and 
Grabowski 2003) (Lee and Irizarry 2003) (Sugnet and others 2006)) (Johnson and others 
2009). SNPs that affect AS at the dopamine D2 receptor (DRD2) are associated with indices 
of DA signaling in vivo and in post-mortem brain samples (Bertolino and others 2009). 
Splice variants of the dopamine D3 receptor (DRD3) with different functional properties are 
also known, and may be associated with SZ risk (Schmauss 1996); (Richtand 2006). 
Disruption of AS has been demonstrated to be a pathogenic mechanism in several diseases, 
including myotonic dystrophy, neurofibromatosis, cystic fibrosis, fronto-temporal dementia, 
certain thalassemias, spinal muscular atrophy and multiple sclerosis (Ranum and Cooper 
2006) (Osborne and Thornton 2006) (Garcia-Blanco and others 2004) (Zatkova and others 
2004); (Steiner and others 2004) (Fackenthal and Godley 2008) (Gregory and others 2007).
Our association analyses provide mixed support for a link between SLC6A3 polymorphisms 
and SZ pathogenesis. In support, we find replicated genetic associations in our Bulgarian/US 
samples that suggest two clusters of risk-conferring SNPs in the third and fourth introns 
(Supplementary Figure SF1a, Figure 1). When we analyzed tag SNPs capturing the 
haplotype information spanning the cassette exon, we found significant risk for SZ conferred 
by a common haplotype incorporating these risk alleles. This result is supported by our 
observation that splicing reporter constructs incorporating the putative risk haplotype have 
higher levels of E3b inclusion compared with constructs bearing the non-risk haplotypes. In 
contrast, we did not find support for association with these SNPs among available GWAS 
samples.
The dopamine transporter has also been implicated in several other neuropsychiatric 
disorders, including Parkinson’s disease (Pellicano and others 2007), early onset bipolar 
disorder (Mick and others 2008), attention deficit hyperactivity disorder (Bellgrove and 
others 2005; Brookes and others 2006); alcoholism (Gorwood and others 2003); cocaine 
addiction (Guindalini and others 2006); smoking (O’Gara and others 2007) and Tourette’s 
syndrome (Tarnok and others 2007). Like the SZ association studies, the majority of these 
studies have solely analyzed the 3′ VNTR. It may be worthwhile to reconsider associations 
with other polymorphisms and the potential impact of splice variation in the light of the 
present analyses.
In conclusion, we report detailed fine-mapping and functional analyses at SLC6A3. Our 
analyses identified a novel cassette exon at SLC6A3 that is alternatively spliced. Genomic 
variation affects the splicing of this exon, but statistical associations were not consistent 
across five independent samples. Further studies are required to fully characterize this 
process and its possible links to neuropsychiatric disorders.
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Refer to Web version on PubMed Central for supplementary material.
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Predicted exon E3b and location of significant SNPs. Top panel: SLC6A3 transcription unit. 
The horizontal line represents the gene, with exons as vertical bars crossing the line. 
Nominally significant SNPs are shown as thin vertical lines that do not cross the horizontal 
lines. The arrow indicates the orientation of transcription. Middle panel: Predicted cassette 
exon E3b. Diagram of genomic region from exon 3 (E3) through exon 4 (E4) of SLC6A3. 
Vertical lines with labels indicate schizophrenia-associated SNPs or SNPs in significant LD 
with SZ-associated SNPs in the PITT/Bulgarian samples. The long form of E3b (using the 
downstream 5′ splice site underlined in the bottom panel) is represented. Bottom panel: 
Sequence of E3b and flanking intron regions. The predicted 3′ splice site region is 
underlined. This contains two potential intron-terminating trinucleotides in tandem 
(aagGTAG). The two strongest 5′ splice site motifs are underlined and highlighted in gray. 
The exon sequence between the first 3′ splice site (aag/G) and the first 5′ splice site (AAG/
gtatgc) is in bold uppercase. The exon sequence between the two 5′ splice sites is in bold 
lower case. The first in-frame stop codons within E3b are highlighted in gray: TAA is 
encountered if the upstream 3′ splice site is used, TGA is encountered if the downstream 3′ 
splice site is used. PITT/Bulgarian Schizophrenia-associated SNP positions are boxed; the 
risk-associated allele is shown in each case.
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Conservation of E3b features among simian primates. Top panel: Multiple sequence 
alignment generated with Clustal 2.0.5. Solid outline: predicted 3′ splice sites. The tandem 
intron-terminating trinucleotide motifs are underlined. Dashed outline: predicted 5′ splice 
sites. Light gray: first in-frame stop codon when the downstream 3′ splice site is used. In 
Marmoset, the first in-frame stop codon lies within the omitted sequence. Dark gray: first in-
frame stop codon when the upstream 3′ splice site is used. Bottom panel: Conservation plot 
for the E3b region. Conservation scores were calculated using the Clustal X software for 
every column of the multiple sequence alignment that contained a non-gap symbol in 
human. The graph was smoothed by plotting the moving averages of the scores for every 30 
columns. The rectangle indicates the region from the upstream 3′ss of E3b to the 
downstream 5′ splice site highlighted in the top panel.
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Alternative splicing of SLC6A3 exon E3b in post-mortem human substantia nigra. Top left 
panel: Schematic (not drawn to scale) of the region comprising exons 2 through 15 of the 
primary SLC6A3 transcript and spliced mRNAs. Vertical bars indicate the omission of exons 
6–14 from the diagram. The diagram illustrates skipping and inclusion of E3b and use of 
two alternative E3b 5′ splice sites spaced 363bp apart. The locations and orientations 
(forward or reverse) of primers used for RT-PCR are shown by arrows above or below the 
corresponding exons (primer sequences are given in Supplementary Methods Section). Note 
that the intron regions flanking E3b measure 6.4 and 2.3 kb, respectively, precluding 
amplification of unprocessed pre-mRNA with any of the primer combinations under the 
PCR conditions used. Top right panel: RT-PCR analysis of E3b splicing. mRNA from 
normal adult substantia nigra substantia nigra was reverse-transcribed with oligo-dT primer 
and the cDNA was subjected to 20 cycles of PCR with primers against exon E2 (E2.F) and 
E15 (E15.R). The products were diluted and subjected to re-amplification with different 
combinations of nested primers targeting exons E2 through E5. The primer combinations for 
the nested PCR and the expected sizes of amplimers corresponding to E3b(+) and E3b(−) 
isoforms are indicated above the gel lanes; E3b(+) long and E3b(+) short correspond to use 
of the distal or proximal 5′ splice sites for E3b, respectively. The sizes of E3b(+) amplimers 
shown correspond to use of the first of the two tandem 3′ splice sites; use of the second 3′ 
splice site shortens the products by four nt (see bottom panel). The number of cycles used 
in the nested PCR reaction is indicated below each lane. Note that in lanes 2 (E2 + E5 
primers) and 3 (E3 + E4 primers), the E3b(+) amplimers are not visible because they are 
much less abundant than the E3b(−) amplimers. The identities of amplimers incorporating 
exon E3b were verified by sequencing. The identities of the large amplimers in lanes 3 
(faint) and 4 have not been investigated. The same results were obtained when the reverse 
primer in the primary amplification targeted exon E5, E13, or E15. When the primary PCR 
was performed on the same RNA samples without reverse transcription, no amplimers were 
observed with any of the nested PCR reactions using the same number of cycles (not 
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shown). Bottom panel: Sequencing E3b(+) amplimers across the E3/E3b junction shows that 
both of the tandem 3′ splice sites for exon E3b are used. E3b begins at nucleotide 206 in this 
representative sequencing trace. Upstream of this position the sequence trace is 
homogeneous (corresponding to the end of exon E3), but downstream it is a mixture of two 
sequences that correspond to use of the two different 3′ splice sites to begin E3b. The two 
predicted E3/E3b junction sequences are aligned below the trace. Nucleotides in lower case 
mark the beginning of the alternatively spliced cassette exon E3b. Four additional 
nucleotides (GTAG) are spliced out as part of the intron when the downstream site is used 
(lower sequence).
Talkowski et al. Page 20














Effect of putative schizophrenia-associated SNPs on splicing of E3b in cell transfection 
assays. Top panel: Structure of transfection constructs (not drawn to scale; details in text). 
pCMV: promoter and transcription start site from CMV. SV40 pA: 3′ cleavage/
polyadenylation cassette from SV40. Constructs contain the entire 9 kb intron 3 sequence; 
thus, RT-PCR with the indicated primers (location shown by arrows) only detects processed 
transcripts. The positions of the SZ-associated SNPs within intron 3 are shown by ovals. 
Diagonal lines indicate the alternative splicing events identified by RT-PCR analysis, 
including the use of alternative 5′ splice sites for E3b (the alternative 3′ splice sites for E3b 
are only four nt apart and are not distinguished in these experiments). Middle panel: 
Examples of transfection results showing a non-PITT risk-associated (12155) and a risk-
associated (12249) construct expressed in SH-SY5Y cells. RNA was isolated from each of 
three transfection replicates for each construct and analyzed by reverse transcription with 
random hexamers followed by PCR with primers E3.F1 (within SLC6A3 exon 3) and 
DAT.E4.R2 (within SLC6A3 exon 4) (arrows in top panel). Amplimers were separated on 
2% agarose and stained with GelStar (Lonza). Identities and sizes of bands corresponding to 
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alternatively spliced isoforms are indicated at the left (not drawn to scale; sizes correspond 
to use of the first or second 3′ splice site of E3b). Sizes of molecular weight markers (M) are 
shown at the right. C1: 12155 transfection, -RT control. C2: 12249 transfection, –RT 
control. C3: RT-PCR of RNA from untransfected cells. Bottom panel: Quantification of 
E3b alternative splicing in transfection experiments for five different “PITT risk” haplotype 
constructs and five different “non-risk” haplotypes. Gel images were captured digitally and 
analyzed using NIH ImageJ software. The vertical axis (E3b+/total) represents the 
proportion of total SLC6A3 mRNA that contains exon E3b, taking into account all the 
amplimer species corresponding to use of different 5′ splice sites for E3b. The average of 
three replicates and the standard deviation is shown in each case. Results are also shown 
from HeLa cell transfections for 12155 (“non-risk”) and 12154 (“risk”). Wilcoxon’s rank 
sum test indicated that the differences in average values for percent E3b inclusion between 
risk and non-risk constructs was significant at P < 0.005 (wnon-risk = 15, wrisk = 40). 
Analysis of variance showed that the differences in average E3b inclusion across the entire 
set of constructs were significant (F = 4.25, P < 0.01), whereas those among risk or non-risk 
constructs were not (Frisk = 0.938; Fnon-risk = 0.39; P ≫ 0.05 in both cases). Application of 
Student’s t-test to the pooled risk versus pooled non-risk data confirmed that inclusion of 
E3b was significantly higher for risk than for non-risk constructs (t = 5.85, P < 0.001).
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Enhancement of E3b inclusion maps to SNPs flanking E3b. Top panel: Diagram of 
mapping strategy by exchange of DNA between putative “PITT risk” and “non-risk” 
constructs. The location of primers for RT-PCR is shown by the black arrows. Bottom 
panel: Results of RT-PCR assay after transfection into SH-SY5Y cells. Procedures as in 
Figure 4. Exchanging the region immediately flanking E3b confers increased inclusion of 
E3b on a “non-risk” construct, as shown by quantification of the proportion of E3b(+) to 
total DAT mRNA at the right. Student’s t-test showed that the difference in E3b inclusion 
between the swap construct and the non-risk construct was significant (t = 5.00, P < 0.001), 
whereas the swap construct and the risk construct did not differ significantly (t = 0.218, P > 
0.1).
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ΔCt values for E3b+ and E3b− transcripts in post- mortem human substantia nigra. ΔCt 
values for cases and controls were calculated as described. Gray and black circles designate 
cases and controls, respectively. The straight line represents the regression for the entire 
sample.
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